Innovus Pharma Announces The Beginning Of Patient Enrollment In Its Post-Marketing Ejectdelay Clinical Study In The Middle East
5/15/2014 11:55:25 AM
SAN DIEGO, May 15, 2014 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTCBB:INNV) today announced that patient enrollment has begun in its EjectDelay™ post-marketing clinical study in Lebanon. The study is being run at the Lebanese-Canadian Hospital in Beirut, Lebanon.
Help employers find you! Check out all the jobs and post your resume.
comments powered by